
ALT A graph from an Original Article published in the New England Journal of Medicine article titled "Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity." The graph shows effect of retatrutide on body weight. The trial name, TRIUMPH-1, is in parentheses after the title. The NEJM identity sits at the bottom.

ALT Three graphs showing Kaplan–Meier estimates for prespecified events as adjudicated by the clinical-events committee at 3 years. Panel A shows freedom from death from any cause or hospitalization for heart failure (second coprimary end point), Panel B survival, and Panel C freedom from hospitalization for heart failure.

ALT A graph from the Original Article "Pulmonary Denervation for Heart Failure–Related Pulmonary Hypertension." The trial name, PADN-HF-PH, is in parentheses after the title. The graph shows the time-to-event analysis involving the patients who had clinical worsening, a composite of death, heart or lung transplantation, hospitalization for heart failure, outpatient worsening of heart failure, or a decline in the 6-minute walk distance. The trial results are being presented at the European Society of Cardiology Congress 2026. The logo of the New England Journal of Medicine is at the bottom.

























